Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 479

1.

Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.

Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J.

Drug Alcohol Depend. 2000 Dec 22;61(1):85-94.

PMID:
11064186
2.

Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.

Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP.

Psychopharmacology (Berl). 1999 Jan;141(1):37-46.

PMID:
9952063
3.

Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.

Strain EC, Stoller K, Walsh SL, Bigelow GE.

Psychopharmacology (Berl). 2000 Mar;148(4):374-83.

PMID:
10928310
4.
5.

Buprenorphine and naloxone interactions in methadone maintenance patients.

Mendelson J, Jones RT, Welm S, Brown J, Batki SL.

Biol Psychiatry. 1997 Jun 1;41(11):1095-101.

PMID:
9146820
6.

Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

Mendelson J, Jones RT.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S29-37. Review.

PMID:
12738348
7.

Buprenorphine and naloxone interactions in opiate-dependent volunteers.

Mendelson J, Jones RT, Fernandez I, Welm S, Melby AK, Baggott MJ.

Clin Pharmacol Ther. 1996 Jul;60(1):105-14.

PMID:
8689806
8.

Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.

Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN.

Drug Alcohol Depend. 1998 Mar 1;50(1):1-8.

PMID:
9589267
9.

Effects of buprenorphine/naloxone in opioid-dependent humans.

Stoller KB, Bigelow GE, Walsh SL, Strain EC.

Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

PMID:
11351930
10.

Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.

Ciraulo DA, Hitzemann RJ, Somoza E, Knapp CM, Rotrosen J, Sarid-Segal O, Ciraulo AM, Greenblatt DJ, Chiang CN.

J Clin Pharmacol. 2006 Feb;46(2):179-92.

PMID:
16432270
11.
12.

Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.

Correia CJ, Walsh SL, Bigelow GE, Strain EC.

Psychopharmacology (Berl). 2006 Dec;189(3):297-306. Epub 2006 Sep 30.

PMID:
17013637
13.

A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.

Mintzer MZ, Correia CJ, Strain EC.

Drug Alcohol Depend. 2004 May 10;74(2):205-9.

PMID:
15099664
14.

The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.

Mammen K, Bell J.

Expert Opin Pharmacother. 2009 Oct;10(15):2537-44. doi: 10.1517/14656560903213405. Review.

PMID:
19708849
15.

Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, Collins J, Raisch D, Casadonte P, Goldsmith RJ, Ling W, Malkerneker U, McNicholas L, Renner J, Stine S, Tusel D; Buprenorphine/Naloxone Collaborative Study Group.

N Engl J Med. 2003 Sep 4;349(10):949-58.

16.

Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.

Eissenberg T, Greenwald MK, Johnson RE, Liebson IA, Bigelow GE, Stitzer ML.

J Pharmacol Exp Ther. 1996 Feb;276(2):449-59.

PMID:
8632309
17.

Sublingual buprenorphine is effective in the treatment of chronic pain syndrome.

Malinoff HL, Barkin RL, Wilson G.

Am J Ther. 2005 Sep-Oct;12(5):379-84.

PMID:
16148422
18.

Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.

Strain EC, Walsh SL, Bigelow GE.

Psychopharmacology (Berl). 2002 Jan;159(2):161-6. Epub 2001 Oct 12.

PMID:
11862344
19.

Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.

Webster L, Hjelmström P, Sumner M, Gunderson EW.

J Addict Dis. 2016 Oct-Dec;35(4):325-338. Epub 2016 Jun 7.

PMID:
27267785
20.

Buprenorphine in the treatment of opiate dependence.

Wesson DR, Smith DE.

J Psychoactive Drugs. 2010 Jun;42(2):161-75.

PMID:
20648912

Supplemental Content

Support Center